Mersana Therapeutics, Inc. is a pharmaceutical company based in the United States that focuses on developing targeted drugs with enhanced tolerability for patients. With an ESG score of 27.4, the company is assessed as having a medium risk. Mersana Therapeutics utilizes its proprietary ADC platforms to create innovative treatments, including programs targeting B7-H4 and human epidermal growth factor receptor 2. This clinical-stage biopharmaceutical company also has preclinical candidates that leverage its Immunosynthen platform to target tumor-associated antigens.